Company releases

Investors

Home

Nightingale as an investment

Key strengths

CEO's greetings

Operational environment

Strategy

Dividends policy

Financial information

Key figures

Share and shareholders

Governance

Governance principles

General Meeting

Annual General Meeting 2021

Managers' transactions

Auditor

Certified Adviser

Articles of Association

Investor relations

Releases

Managers' transactions

Reports and presentations

IPO

IPO 2021

Investors

Company releases

18/1/2022 Nightingale introduces combination of its proprietary blood test and genomics: acquires Finnish genetic testing company Negen and launches international centre of excellence for genomic data analysis

2/11/2021 Tuukka Paavola appointed as Chief Financial Officer of Nightingale Health Plc

29/10/2021 Conversion of Nightingale Health Plc’s Series A shares and EMP shares to Series B shares

28/10/2021 Resolutions of Nightingale Health Plc’s Annual General Meeting and Board of Directors

27/10/2021 Nightingale and major Finnish pharmacy chain Yliopiston Apteekki enter into nation-wide distribution partnership of Nightingale's at-home testing solution

13/10/2021 Nightingale and Terveystalo launch a new well-being membership

1/10/2021 Notice to the Annual General Meeting of Nightingale Health Plc

1/10/2021 Nightingale's Annual Report for financial year 2020–2021 published

15/9/2021 Nightingale Health Plc Financial Statements Release 1 July 2020 – 30 June 2021

30/8/2021 Jeffrey Barrett appointed as Chief Scientific Officer of Nightingale Health Plc

9/7/2021 Nightingale Health acquires German digital health company Yolife GmbH

1/7/2021 Nightingale Health quarterly summary of achieved key milestones and reiteration of near-term business targets

29/6/2021 Nightingale secures global scalability of its at-home solution by partnering with at-home blood collection device manufacturer Weavr with new commercial terms and minority investment

23/6/2021 Nightingale successfully completes the first phase of its at-home blood testing pilot

4/5/2021 Nightingale restructures its Management Team and established strategic partnership with Reaktor

29/4/2021 Nightingale Health signed service agreement for health and well-being services in Japan

22/4/2021 Nightingale Health Plc and Terveystalo have entered into strategic partnership agreement

9/4/2021 Nightingale Health Plc’s subsidiary received clinical laboratory certification in Japan

31/3/2021 The cancellation of Nightingale Health Plc’s treasury shares entered in the Trade Register

25/3/2021 Nightingale Health Plc’s ten largest shareholders after the completion of the initial public offering

23/3/2021 Stabilisation measures taken and the end of the stabilisation period; the Board of Directors has resolved on the cancellation of treasury shares

18/3/2021 The IPO of Nightingale has been oversubscribed and the listing will be completed as planned – trading in the series B shares is expected to commence on 19 March 2021

16/3/2021 Public offering of Nightingale has been oversubscribed and therefore the subscription period has been discontinued

15/3/2021 Nightingale Health Plc comments on the media coverage on its initial public offering

8/3/2021 Nightingale announces a fixed subscription price and publishes a prospectus for its contemplated IPO and listing of its series B shares on Nasdaq First North Growth Market Finland

8/3/2021 Nightingale has applied for its series B shares to be listed on Nasdaq First North Growth Market Finland and commences the initial public offering

For individuals

For business

Nightingale for business

Health initiatives

For investors

Investor pages

Nightingale as an investment

Financial information

Share and shareholders

Governance

Investor relations

Releases

Reports and presentations

IPO

Suomeksi

For research

Nightingale's research services

About us

Get our newsletter

Interested in getting the latest news about Nightingale? Subscribe to our newsletter.

Nightingale Health Oyj

Mannerheimintie 164a, 00300 Helsinki, Finland

Contact →